Insider Trading Alert - TKR, MTOR And ALXN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Aug. 29, 2014, 54 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $310.48 to $19,750,166.52.

Highlighted Stocks Traded by Insiders:

Timken (TKR) - FREE Research Report

Woods Jacqueline F, who is Director at Timken, sold 1,340 shares at $45.43 on Aug. 29, 2014. Following this transaction, the Director owned 17,137 shares meaning that the stake was reduced by 7.25% with the 1,340-share transaction.

The shares most recently traded at $45.79, up $0.36, or 0.79% since the insider transaction. Historical insider transactions for Timken go as follows:

  • 4-Week # shares sold: 1,340
  • 12-Week # shares sold: 1,340
  • 24-Week # shares sold: 3,250

The average volume for Timken has been 1.2 million shares per day over the past 30 days. Timken has a market cap of $4.1 billion and is part of the industrial goods sector and industrial industry. Shares are down 17.76% year-to-date as of the close of trading on Friday.

The Timken Company engineers, manufactures, and markets mechanical components, bearings, and engineered steel bars and tubes worldwide. The stock currently has a dividend yield of 2.21%. The company has a P/E ratio of 17.2. Currently, there are 4 analysts who rate Timken a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TKR - FREE

TheStreet Quant Ratings rates Timken as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and poor profit margins. Get the full Timken Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Meritor (MTOR) - FREE Research Report

Lyons William J, who is Director at Meritor, bought 1,868 shares at $13.59 on Aug. 29, 2014. Following this transaction, the Director owned 33,330 shares meaning that the stake was boosted by 5.94% with the 1,868-share transaction.

The shares most recently traded at $13.70, up $0.11, or 0.77% since the insider transaction. Historical insider transactions for Meritor go as follows:

  • 4-Week # shares bought: 1,868
  • 4-Week # shares sold: 16,414
  • 12-Week # shares bought: 1,868
  • 12-Week # shares sold: 16,414
  • 24-Week # shares bought: 22,042
  • 24-Week # shares sold: 16,414

The average volume for Meritor has been 1.6 million shares per day over the past 30 days. Meritor has a market cap of $1.3 billion and is part of the consumer goods sector and automotive industry. Shares are up 30.68% year-to-date as of the close of trading on Friday.

Meritor, Inc. designs, develops, manufactures, sells, markets, distributes, services, and supports integrated systems, modules, and components to original equipment manufacturers (OEMs) and the aftermarket for the commercial vehicle, transportation, and industrial sectors. The company has a P/E ratio of 4.8. Currently, there are 3 analysts who rate Meritor a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTOR - FREE

TheStreet Quant Ratings rates Meritor as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Meritor Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Bell Leonard, who is Ceo at Alexion Pharmaceuticals, sold 5,912 shares at $169.17 on Aug. 29, 2014. Following this transaction, the Ceo owned 1.0 million shares meaning that the stake was reduced by 0.58% with the 5,912-share transaction.

The shares most recently traded at $169.32, up $0.15, or 0.09% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares sold: 5,912
  • 12-Week # shares sold: 15,777
  • 24-Week # shares sold: 20,587

The average volume for Alexion Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $33.5 billion and is part of the health care sector and drugs industry. Shares are up 27.4% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 85.1. Currently, there are 11 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

China Trade Truce, General Electric and Tesla - 5 Things You Must Know

China Trade Truce, General Electric and Tesla - 5 Things You Must Know

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

Tesla Shares Jump on New $78,000 Model 3 Plan, China Trade War Truce

Tesla Shares Jump on New $78,000 Model 3 Plan, China Trade War Truce

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019